PT1871347T - Composição farmacêutica - Google Patents

Composição farmacêutica

Info

Publication number
PT1871347T
PT1871347T PT67504753T PT06750475T PT1871347T PT 1871347 T PT1871347 T PT 1871347T PT 67504753 T PT67504753 T PT 67504753T PT 06750475 T PT06750475 T PT 06750475T PT 1871347 T PT1871347 T PT 1871347T
Authority
PT
Portugal
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
PT67504753T
Other languages
English (en)
Portuguese (pt)
Inventor
Howard Carter Barry
A Campbell Dwayne
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37115487&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1871347(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT1871347T publication Critical patent/PT1871347T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT67504753T 2005-04-19 2006-04-18 Composição farmacêutica PT1871347T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67280505P 2005-04-19 2005-04-19

Publications (1)

Publication Number Publication Date
PT1871347T true PT1871347T (pt) 2016-11-10

Family

ID=37115487

Family Applications (1)

Application Number Title Priority Date Filing Date
PT67504753T PT1871347T (pt) 2005-04-19 2006-04-18 Composição farmacêutica

Country Status (28)

Country Link
US (3) US8821927B2 (enExample)
EP (1) EP1871347B1 (enExample)
JP (1) JP5202302B2 (enExample)
KR (1) KR101356748B1 (enExample)
CN (1) CN101203211B (enExample)
AR (1) AR054252A1 (enExample)
AU (1) AU2006236423B2 (enExample)
BR (1) BRPI0609962B1 (enExample)
CA (1) CA2606207C (enExample)
CY (1) CY1118179T1 (enExample)
DK (1) DK1871347T3 (enExample)
EA (1) EA200702253A1 (enExample)
ES (1) ES2601503T3 (enExample)
HR (1) HRP20161429T1 (enExample)
HU (1) HUE030982T2 (enExample)
IL (1) IL186336A0 (enExample)
LT (1) LT1871347T (enExample)
MA (1) MA29404B1 (enExample)
MX (1) MX2007013089A (enExample)
NO (1) NO20075111L (enExample)
NZ (1) NZ562223A (enExample)
PE (1) PE20061430A1 (enExample)
PL (1) PL1871347T3 (enExample)
PT (1) PT1871347T (enExample)
SI (1) SI1871347T1 (enExample)
TW (1) TW200716204A (enExample)
WO (1) WO2006113649A1 (enExample)
ZA (1) ZA200708705B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101356748B1 (ko) * 2005-04-19 2014-02-06 스미스클라인 비이참 (코르크) 리미티드 약제 조성물
WO2009137714A2 (en) * 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
EP2158913A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158912A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
WO2010099150A1 (en) * 2009-02-24 2010-09-02 Smithkline Beecham (Cork) Limited Pharmaceutical tablet and process
WO2011039759A1 (en) * 2009-09-29 2011-04-07 Natco Pharma Limited A new process for the preparation of lapatinib and its pharmaceutically acceptable salts
JP5858989B2 (ja) 2010-05-21 2016-02-10 ノバルティス アーゲー 組合せ
US20130072507A1 (en) 2010-05-21 2013-03-21 Glaxosmithkline Llc Combination
PE20131341A1 (es) 2010-08-03 2013-12-07 Altherx Inc Combinaciones de agonistas del receptor beta-3-adrenergico y antagonistas del receptor muscarinico para tratar vejiga hiperactiva
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
EP2958552B1 (en) * 2013-02-19 2017-06-21 Hexal AG Pharmaceutical composition comprising n-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]quinazolin-4-amine or a pharmaceutically acceptable salt, solvate or solvated salt thereof
WO2014170910A1 (en) 2013-04-04 2014-10-23 Natco Pharma Limited Process for the preparation of lapatinib
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
MX2017007054A (es) 2014-12-03 2018-05-02 Velicept Therapeutics Inc Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior.
CN106389373B (zh) * 2015-07-29 2019-07-02 四川科伦药物研究院有限公司 一种二甲苯磺酸拉帕替尼片剂及其制备方法
CN106511289A (zh) * 2015-09-10 2017-03-22 湖北生物医药产业技术研究院有限公司 甲苯磺酸拉帕替尼片剂及其制备方法
CN108290824B (zh) 2015-10-23 2022-03-11 B3Ar治疗股份有限公司 索拉贝隆两性离子及其应用
CA3149796A1 (en) 2019-08-02 2021-02-11 Onehealthcompany, Inc. Anti-cancer agents for the treatment of canine cancers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
SK146199A3 (en) 1997-04-25 2000-06-12 Janssen Pharmaceutica Nv Farnesyltransferase inhibiting quinazolinones
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
CA2413134C (en) 2000-06-30 2010-05-11 Glaxo Group Limited Quinazoline ditosylate salt compounds
US7141576B2 (en) 2001-01-16 2006-11-28 Smithkline Beecham (Cork) Limited Cancer treatment method
AU2003221684A1 (en) 2002-04-08 2003-10-27 Smithkline Beecham Corporation Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
AU2003235470A1 (en) 2002-06-19 2004-01-06 Smithkline Beecham Corporation Predictive markers in cancer therapy
KR101356748B1 (ko) * 2005-04-19 2014-02-06 스미스클라인 비이참 (코르크) 리미티드 약제 조성물

Also Published As

Publication number Publication date
BRPI0609962A2 (pt) 2011-10-11
EP1871347A1 (en) 2008-01-02
JP5202302B2 (ja) 2013-06-05
CN101203211A (zh) 2008-06-18
AR054252A1 (es) 2007-06-13
KR101356748B1 (ko) 2014-02-06
MX2007013089A (es) 2008-01-14
ES2601503T3 (es) 2017-02-15
HUE030982T2 (en) 2017-06-28
NO20075111L (no) 2007-11-16
MA29404B1 (fr) 2008-04-01
PL1871347T3 (pl) 2017-04-28
AU2006236423B2 (en) 2009-12-10
US20080206330A1 (en) 2008-08-28
US20160143909A1 (en) 2016-05-26
CA2606207A1 (en) 2006-10-26
WO2006113649A1 (en) 2006-10-26
HRP20161429T1 (hr) 2016-12-16
US20140335177A1 (en) 2014-11-13
IL186336A0 (en) 2008-01-20
DK1871347T3 (en) 2016-11-28
US8821927B2 (en) 2014-09-02
AU2006236423A1 (en) 2006-10-26
EP1871347A4 (en) 2012-10-31
SI1871347T1 (sl) 2016-11-30
ZA200708705B (en) 2009-12-30
BRPI0609962B1 (pt) 2022-01-18
LT1871347T (lt) 2016-11-10
JP2008536931A (ja) 2008-09-11
CA2606207C (en) 2014-11-18
EP1871347B1 (en) 2016-08-03
NZ562223A (en) 2010-01-29
CY1118179T1 (el) 2017-06-28
PE20061430A1 (es) 2007-01-25
CN101203211B (zh) 2012-08-08
TW200716204A (en) 2007-05-01
KR20080005557A (ko) 2008-01-14
EA200702253A1 (ru) 2008-04-28

Similar Documents

Publication Publication Date Title
IL186336A0 (en) Pharmaceutical composition
GB0513692D0 (en) Novel pharmaceutical compositions
IL177480A0 (en) Pharmaceutical composition
IL188352A0 (en) Pharmaceutical compositions
ZA200804103B (en) Pharmaceutical compositions
IL187748A0 (en) Pharmaceutical compositions containing misoprostal
AP2008004533A0 (en) Pharmaceutical combination
IL192091A0 (en) Pharmaceutical compositions
HU0401177D0 (en) Pharmaceutical composition
EP2124959A4 (en) PHARMACEUTICAL COMPOSITION
GB2411355B (en) Pharmaceutical composition
GB0522045D0 (en) Pharmaceutical compositions
GB0425255D0 (en) Pharmaceutical composition
ZA200804666B (en) Pharmaceutical combination
ZA200701932B (en) Pharmaceutical composition
GB0512643D0 (en) Pharmaceutical compounds
ZA200701931B (en) Pharmaceutical composition
GB0512246D0 (en) Novel pharmaceutical
ZA200803566B (en) Pharmaceutical compositions
GB0514259D0 (en) Pharmaceutical compositions
GB0501475D0 (en) Pharmaceutical compounds
GB0402799D0 (en) Pharmaceutical composition
ZA200803112B (en) Pharmaceutical composition
ZA200800392B (en) Pharmaceutical composition
GB0511801D0 (en) Pharmaceutical composition